Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK588738PMID: 36701505
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 1716-12-7
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of sodium phenylbutyrate or the combination of sodium phenylbutyrate and taurursodiol during breastfeeding. Both sodium phenylbutyrate and taurursodiol are highly protein bound and therefore unlikely to enter milk in clinically important amounts. If sodium phenylbutyrate with or without taurursodiol is required by the mother, it is not a reason to discontinue breastfeeding. Until more data become available, these products should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. Monitoring the breastfed infant for neurotoxicity (excessive sedation, vomiting) during maternal therapy may be advisable.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Sodium Phenylbutyrate
CAS Registry Number
1716-12-7
Drug Class
Breast Feeding
Lactation
Milk, Human
Urea Cycle Disorders
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis.[N Engl J Med. 2020]Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis.Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S, Karam C, Caress JB, Owegi MA, Quick A, et al. N Engl J Med. 2020 Sep 3; 383(10):919-930.
- Relyvrio for ALS.[Med Lett Drugs Ther. 2022]Relyvrio for ALS.. Med Lett Drugs Ther. 2022 Nov 28; 64(1664):190-191.
- New Drug Approved For ALS.[Am J Nurs. 2023]New Drug Approved For ALS.Aschenbrenner DS. Am J Nurs. 2023 Jan 1; 123(1):22-23.
- Review An evaluation of the combination of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis.[Expert Rev Neurother. 2023]Review An evaluation of the combination of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis.Sun Y, Li X, Bedlack R. Expert Rev Neurother. 2023 Jan; 23(1):1-7. Epub 2023 Feb 1.
- Review Sodium Phenylbutyrate and Ursodoxicoltaurine: First Approval.[CNS Drugs. 2022]Review Sodium Phenylbutyrate and Ursodoxicoltaurine: First Approval.Heo YA. CNS Drugs. 2022 Sep; 36(9):1007-1013.
- Sodium Phenylbutyrate - Drugs and Lactation Database (LactMed®)Sodium Phenylbutyrate - Drugs and Lactation Database (LactMed®)
- Lavender - Drugs and Lactation Database (LactMed®)Lavender - Drugs and Lactation Database (LactMed®)
- eggc.vipnaw (0)BioProject
Your browsing activity is empty.
Activity recording is turned off.
See more...